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Conjugation of ISG15 inhibits replication of several viruses. Here, using an expression system for assaying human andmouse
ISG15 conjugations (ISGylations), we have demonstrated that vaccinia virus E3 protein binds and antagonizes human and
mouse ISG15modification. To study ISGylation importance in poxvirus infection, we used a mouse model that expresses decon-
jugating proteases. Our results indicate that ISGylation restricts in vitro replication of the vaccinia virus VVE3L mutant but
unconjugated ISG15 is crucial to counteract the inflammatory response produced after VVE3L infection.
Type I interferon (alpha/beta interferon [IFN-/]) is essentialfor controlling the replication of viruses in their mammalian
hosts. Binding of IFN-/ to its receptor activates the Janus kinase
signal transducer and activator of transcription (JAK/STAT)
pathway and consequently leads to the upregulation of hundreds
of IFN-stimulated genes (ISG) (1). One of the most highly in-
duced genes is ISG15, which encodes a small ubiquitin-like (UBL)
protein of 17 kDa that forms covalent conjugates with cellular and
viral proteins mediating a considerable antiviral response (2, 3).
ISG15 is composed of two domains, each of which carries high
sequence and structural similarity to ubiquitin (UB) (33 and 32%
for the N- and C-terminal domains, respectively [4]). Conjuga-
tion of ISG15 to its protein substrates follows principles similar to
those with UB, requiring an E1-activating enzyme (UBE1L), an
E2-conjugating enzyme (UbcH8), and an E3 ligase, which in hu-
mans is mainly Herc5, while in mice mHerc6 performs this func-
tion (5, 6).
The mechanism responsible for the antiviral activity of ISG15
is not clearly understood. ISG15 has been reported to be conju-
gated to proteins involved in direct or indirect antiviral activity,
including RIG-I, JAK1, STAT1, interferon regulatory factor 3
(IRF3), and protein kinase R (PKR) (7, 8). It has also been shown
that IRF3 ISG15 conjugation (ISGylation) prevents its ubiquitina-
tion and degradation, enhancing its translocation to the nucleus.
Consequently, the relative amount of IRF3 is reduced in ISG15/
cells compared to that in ISG15/ cells (9). ISG15 negatively
regulates important cell signaling pathways, such as RIG-I-like
receptor (RLR) signaling and activation of NF-B (10, 11). On the
other hand, protein de-ISGylation negatively regulates the JAK/
STAT pathway (7). It has also been suggested that conjugation of
ISG15 to viral proteins has detrimental effects in viral replication.
Finally, free, unconjugated ISG15 appear to have antiviral prop-
erties, at least for some viruses (12).
Studies with several viruses have verified that ISG15 plays an
essential role in the antiviral response (13, 14). Thus, evidence
supports the antiviral activity of both conjugated and unconju-
gated ISG15. For Sindbis virus, the increased lethality seen in
ISG15/mice can be rescued by a recombinant virus expressing
wild-type (WT) ISG15 but not mutant ISG15, the latter not being
able to form conjugates in vitro (15). In contrast, two reports
showed that free ISG15, in the absence of its conjugation cascade,
inhibited the release of Ebola virus-like particles (16, 17). Free
ISG15 but not ISGylation promotes antiviral responses against
Chikungunya virus infection (12). Previously, we described ISG15
upregulation using cDNA microarrays after infection of HeLa
cells with the attenuated vaccinia virus (VACV) strains MVA and
NYVAC, an effect not observed after infection with the virulent
strainWR (18–20). Also, we have demonstrated the importance of
ISG15 in the context of poxvirus infection (21). We evaluated
disease progression in ISG15/ and ISG15/ mice after infec-
tion with WR and with the attenuated mutant VVE3L, which
lacks the viral early protein E3, using different routes of inocula-
tion. We determined that E3 blocked the antiviral effect of ISG15.
However, themechanismbywhich E3 is able to block ISG15 is still
unknown. The E3 protein also represses the host cell antiviral
response by multiple mechanisms, including inhibition of PKR
and RNase L, two enzymes induced by IFN.When activated, PKR
and RNase L trigger a global inhibition of protein synthesis and of
virus replication (22, 23) through the phosphorylation of eIF-2
(for PKR) and breakdown of RNA (for RNase L). E3 also blocks
induction of genes, such as those encoding IFN-/, through in-
hibition of phosphorylation of the transcription factors IRF3 and
IRF7 (24, 25) and prevention of NF- activation (26).
Taking into account the important role of ISG15 in establish-
ing the antiviral state of the infected cell, several viruses have de-
veloped strategies to counteract its antiviral action. Here, we
wanted to investigate if E3 was able to inhibit ISG15 as previously
described for the NS1 protein of influenza B virus (27, 28). Influ-
enza BNS1, a proteinwith structural and functional similarities to
E3 (29), binds and inhibits human but not mouse ISG15 (27, 28).
Our first approach was to test whether E3 protein was binding to
the ISG15 protein of human or mouse origin. Previously, we had
described that in themouse, ISG15 binds the E3 protein in a PKR-
independent manner (21). To confirm these results and to extend
these studies to the human model, pulldown experiments were
performed. For these assays, expression plasmids with glutathione
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S-transferase (GST) fused in frame to human or mouse ISG15
were generated and coexpressed in 293T cells with plasmids en-
coding the entire viral E3 gene or B/NS1, which was used as a
control. Protein lysates were subjected to GST pull-down, and
precipitated proteins were analyzed by Western blotting using
E3-, NS1-, and GST-specific antibodies (Fig. 1, left panels). In the
whole-cell lysates (Fig. 1A, lower-left panels), similar expression
levels of E3 and GST fusions were observed. In both cases, GST-
hISG15 and GST-mISG15 precipitated with E3 (Fig. 1A, upper-
left panels), indicating that E3 is able to interact with human and
also murine ISG15. E3 has two domains: an N-terminal domain,
involved in the direct inhibition of the IFN-induced double-
strandedRNA (dsRNA)-dependent protein kinase PKR innuclear
localization and in Z-DNA binding (30–32), and a C-terminal
FIG 1 The VACVE3 protein binds to ISG15 from human andmurine origin and blocks ISGylation. (A) The C-terminal domain of E3 interacts with human and
mouse ISG15. 293T cells were transfected with the indicated plasmids, GST, GST-hISG15 (human origin), or GST-mISG15 (murine origin), and cotransfected
with B/NS1 from influenza B/Yamagata/88 virus (Yam88/NS1), the E3 protein from VACV (Western Reserve strain), the last 26 C-terminal amino acids of E3
(VVE3L83N), or the first 83 N-terminal amino acids of E3 (VVE3L26C). Cell lysates were subjected to GST pulldown, and Western blot analysis of
precipitated proteins was performed using GST-, NS1/B-, and E3-specific antibodies. Molecular mass markers (kDa) are shown to the right. Three independent
experiments were conducted, and a representative image is shown. (B and C) E3 inhibits human and mouse ISGylation. 293T cells were transfected with the
indicated plasmids, and then 24 h later, cell lysates were analyzed byWestern blotting for V5-ISG15 conjugation using a V5 tag-specific antibody. The expression
of the different E3 domains was analyzed by Western blotting using a specific antibody against E3. Tubulin was used as loading control. (B) Human E1, E2, E3,
andV5-hISG15plasmidswere cotransfectedwith plasmids encodingB/NS1 or E3 protein fromVACV(WRstrain), eitherwith the last 26C-terminal amino acids
of E3 (VVE3L83N) or with the first 83 N-terminal amino acids of E3 (VVE3L26C). The concentration of conjugationmachinery plasmids was kept constant,
while the relative amounts of hISG15 plasmid were lowered and hISG15 was replaced by B/NS1. In the line indicated as ISG15-AA, a control of nonconjugated
ISG15 (v5-hISG15-AA) was transfected with human E1, E2, and E3. Three independent experiments were performed, and a representative image is shown. (C)
Murine E1, E2, E3, andV5-hISG15 plasmids were cotransfectedwith plasmids encoding B/NS1 or E3, either with the last 26 C-terminal amino acids of E3 or with
the first 83 N-terminal amino acids of E3. In the line indicated as ISG15-AA, a control of nonconjugated ISG15 (v5-mISG15-AA) was transfected with murine
E1, E2, and E3. Three independent experiments were performed, and a representative image is shown.
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domain, which contains the dsRNA-binding domain required for
IFN resistance and for the broad-host-range phenotype of the
virus (30, 33). To studywhether the specific region responsible for
the binding between the E3 protein and ISG15 was the same in the
murine and human systems, we constructed plasmids expressing
two portions of the E3 protein: the first was 165 amino acids in
length and the last was 108 amino acids. We then performed sim-
ilar pulldown experiments using the two portions of the E3 pro-
tein. The C-terminal domain of E3 is needed for its interaction
withmurine or human ISG15 (Fig. 1A, right panels). These results
indicate that VACV E3 has a higher binding permissibility for
ISG15 from multiple species than B/NS1, because differences be-
tween mouse and human ISG15 sequence are not influencing E3
protein binding ability. However, substituting the mouse se-
quence (QNCSE) for the human hinge sequence (DKCDE) in
human ISG15 resulted in a total loss of NS1B binding (34).
ISGylation) to substrate proteins occurs in amanner similar to
that of UB conjugation, by utilizing activating, conjugating, and
ligating enzymes to facilitate the addition of ISG15 to specific
lysine residues. Although we defined that E3 regulates ISG15 ac-
tivity, the only evidence until now that suggests that E3 blocks the
ISGylation process is the increased level of ISGylated complexes
observed in VVE3L-infected mouse lung homogenates (21). To
elucidatewhether E3 blocks ISGylation activity and to further gain
insights into its mechanism, we performed an in vitro assay that
allowed us to study the impact of the expression of E3 on protein
ISGylation.We transfected 293 cells with ISG15 and its specific E1
(UBE1), E2 (UbcM8), and E3 (HERC5) enzyme expression plas-
mids to evaluate ISGylated protein levels in both human andmu-
rine systems. Next, we compared levels of ISGylated protein after
cotransfection of the E3 plasmid with the plasmids described
above. Using the human ISGylation system, we observed a de-
crease in total ISGylation when E3 was coexpressed. This suggests
that E3might be blocking the ISGylation activity of human ISG15
(Fig. 1B).When we performed similar experiments using the mu-
rine system, we also observed a decrease in the ISGylation levels
when the entire E3 VACV protein was cotransfected, although the
efficacy of this blockage is lower than that observed in the human
system (Fig. 1C). Interestingly, both C- and N-terminal domains
of E3 are required for ISGylation inhibition, indicating that E3
binding to ISG15 is not sufficient for ISGylation inhibition.
Host restriction of a virus is driven by its ability to counteract
specific components of the innate immune response in selected
species. In the context of influenza B virus, its inability to block
ISGylation in mice and in other hosts as well may contribute to
limiting the host range of the virus.Moreover, itmight account for
the increased susceptibility of ISG15/ mice to influenza virus
infection, as previously described (35). In contrast, the capacity of
VACV to counteract ISGylation by E3 in the murine system cor-
related with a lack of differences in pathogenesis between
ISG15/ and ISG15/ cells infected with VACV, as we previ-
ously reported (21).
According to the aforementioned considerations, we can spec-
ulate that subversion of ISGylation may control virus replication
in mouse infection. In order to elucidate this question and to
define the roles between ISG15 and ISGylation in the context of
VACV infection, we used a transgenic mouse model in which
proteases with deconjugating activity (OTU) are expressed (36).
Therefore, although ISG15 is expressed, ISGylation is completely
repressed. We have previously reported that the attenuated
VVE3L virus was able to grow in ISG15/ mouse embryonic
fibroblasts (MEFs) (21). Our next step was to understand if this
phenotype was also observed in OTUMEFs. The cytopathic effect
(CPE) observed in OTUMEFs after VACV (WR strain) infection
(0.1 PFU/cell, 24 h) was similar to that with ISG15/ or
ISG15/ cells (data not shown). However, the CPE after
VVE3L infection in OTU cells was similar to that in ISG15/
cells and was markedly increased compared to that observed in
ISG15/ cells (data not shown). VACV viral titers were slightly
increased in ISG15/ and OTU cells compared to those in
ISG15/ cells (Fig. 2A). On the other hand, a significant increase
of VVE3L yields was observed in ISG15/ and OTU cells com-
pared to results for ISG15/ cells (Fig. 2B). In the VVE3L-
infected ISG15/ and OTU cells, the increase in virus titers cor-
relatedwith increase in cellularmortality (Fig. 2D), indicating that
VVE3L overcomes viral growth blockage only in the absence of
ISGylation. This suggests that E3-mediated ISGylation inhibition
might account for similar levels in VACV replication in ISG15/
ISG15/ or OTU cells, thus validating our in vitro assays shown
in Fig. 1.
FIG 2 Effect of ISG15 and ISGylation on virus growth and cytotoxicity after
infection of MEFs with VACV or VVE3L viruses. (A) ISG15/, out, or
ISG15/ mice were mock infected or infected at 0.1 PFU/cell with VACV
(WR) or VVE3L. At different times postinfection, cells were harvested and
virus yields were determined by plaque assay for VACV or by immunostaining
forVVE3L. (B)Cellular viability of ISG15/, out, or ISG15/ cells infected
with VACV (WR) or VVE3L virus at the indicated multiplicity of infection
(MOI) from 0.01 to 10 PFU/cell. Twenty-four hours postinfection (hpi), the
medium was removed and cytolysis was determined by crystal violet staining.
The percentage of viable cells after infection was calculated assuming the sur-
vival rate of uninfected cells to be 100%. Three independent experiments were
carried out, and a representative experiment is shown. Error bars indicate the
standard deviations of the means. Student’s t test was performed to determine
the P value. (, P	 0.05; , P	 0.01).
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To expand these studies to an in vivo model, transgenic OTU
and wild-type mice were inoculated intranasally with different
doses of VACV (WR strain). We examined the degree of viral
pathogenesis during the first days of the infection, and no differ-
ences in weight loss and in mortality were detected between OTU
and wild-type mice (Fig. 3A). Although at the higher dose of
VACV, all OTU transgenic animals died, while the WT animals
were still alive, we do not think these are significant differences,
since 2 days later, all the WT infected animals also succumbed to
infection. This result indicates that there were no differences in
pathogenesis with VACV-infected ISG15/ or OTU mice in
comparison to that with ISG15/mice. However, in the case of
VVE3L, an enhanced inflammatory response and mortality are
observed only after ISG15/high-dose infection (21). To analyze
whether the cause of VVE3L-associated increased pathogenicity
in infected ISG15/ mice was due to a lack of ISGylation, we
infected OTU transgenic mice with VVE3L virus. OTU,
ISG15/, and ISG15/ mice were inoculated intranasally with
108 PFU of VVE3L per mouse, and weight loss and mortality
were evaluated. As previously described (21), VVE3L-infected
ISG15/ mice displayed mild disease symptoms within 3 days,
and 25%of themdied at 1 day postinfection (dpi) after a high dose
in the absence of viral replication in the lungs (Fig. 3B). Surpris-
ingly, when ISGylation was decreased due to the expression of the
OTU transgene, VVE3Lwas still attenuated (Fig. 3). The animals
also displayed mild signs of disease at 3 dpi, but all the animals
recovered at the endpoint of the experiment (Fig. 3B). Also,
VV
3L virus could not be detected in lung lysates from either
OTU, ISG15/, nor ISG15/ animals (Fig. 3C). This result sug-
gests that the presence of unconjugated ISG15, which is not af-
fected in the OTU transgenic mouse, is a requirement tomaintain
the attenuated phenotype ofVVE3L virus in vivo (Fig. 3A andB).
Histological examination of lung tissues at 1 dpi showed that
ISG15/ or OTU animals infected with VVE3L virus had no
inflammatory cells infiltrating the lung parenchyma. In contrast,
lung sections obtained from VVE3L-infected ISG15/ mice
presented a severe inflammation pattern, with alveolar wall thick-
ening and infiltration of inflammatory cells (Fig. 4A). Lung in-
flammation was also drastically reduced in infected OTU mice.
These results suggest that unconjugated ISG15 is responsible for
counteracting the development of an exacerbated inflammatory
response after a high dose of VVE3L virus. To analyze the state of
ISGylation in the VACV- or VVE3L-infected mice, lungs were
homogenized and ISG15 levels were determined byWestern blot-
ting. While ISG15/mice do not express ISG15 (Fig. 4B), lungs
from OTU mice showed only unconjugated ISG15, as expected,
whereas the homogenates from ISG15/mice showed free ISG15
and ISG15 conjugated to cellular targets (Fig. 4B). The conjuga-
tion of ISG15 to its targets proteins was considerably enhanced in
lung extracts from mice infected with VVE3L in comparison to
those infected with VACV. This result suggests that E3 also was
able to inhibit the ISGylation in vivo, validating our in vitro anal-
ysis (Fig. 1). Since the inflammatory response might explain the
rapid signs of illness in high-dose VVE3L-infected ISG15/
mice, we measured serum cytokine levels (interleukin 6 [IL-6],
tumor necrosis factor alpha [TNF-], IL-10, monocyte chemoat-
tractant protein 1, IFN-, and IL-12 p70) at early times postinfec-
tion in the infected ISG15/, ISG15/, orOTUmice. IL-6 levels
were very low and were similar in serum from VVE3L-infected
OTU or ISG15/ animals (Fig. 4C). In contrast, ISG15/mice
FIG 3 A decrease in the ISGylation levels does not vary VACV pathogenesis.
(A) Transgenic OTU (ISGylation deficient; gray circles) or wild-type (white
circles) mice were infected intranasally with 105, 5  105, or 5  106 PFU/
mouse of VACV (WR strain). Infectedmice were weighed daily, and themean
percentage weight loss of each group (n 12) was compared with the weight
immediately before the infection (lower panels). The upper panels show the
survival rate. Two independent experiments were carried out, and a represen-
tative experiment is shown. Error bars indicate the standard deviations of the
means. Student’s t test was performed to determine the P value. (, P	 0.05;
, P	 0.01). (B) VVE3L infection is attenuated in the OTUmice. ISG15/
(black circles), transgenic OTU (gray circles), orWT (white circles) mice were
infected by the intranasal route with 108 PFU/mouse. Infected mice were
weighed individually daily, and themean percentage weight loss of each group
(n 12) was compared with the weight immediately prior to infection (lower
panels). The upper panels show the survival rate. Two independent experi-
ments were carried out, and a representative experiment is shown. Error bars
indicate the standard deviations of themeans. Student’s t test was performed to
determine the P value. (, P 	 0.05; , P 	 0.01). (C) Viral replication of
different VACV strains in infected ISG15/, ISG15/, andOTUmice. At 24
hpi, lung homogenates were titrated by plaque assay in BSC40 (for WR) or by
immunostaining in BHK-21 cells (for VVE3L). Three independent experi-
ments were carried out, and a representative experiment is shown. Results
represent the means  SD for individual samples of 6 mice/day/group. Stu-
dent’s t test was performed to determine the P value. (, P	 0.01). The dotted
line represented the detection limit.
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FIG 4 Free ISG15 is essential for controlling the proinflammatory response after infection of VVE3L. (A) Histopathology of lungs from ISG15/, OTU, and
ISG15/mice intranasally infected with VVE3L (108 PFU/mouse). At 24 hpi, infected lungs were resected, sectioned, and stainedwith hematoxylin and eosin.
Three independent experiments were performed, using 3 animals each, for each group of animals. Representative fields of the 9 histology specimens analyzed are
shown at amagnification of100. (B)Western blot of ISG15 in lung homogenates from ISG15/, OTU, and ISG15/mice intranasally infected for 24 h with
VACV or VVE3L (108 PFU/mouse). Each sample represents pools from 6 mice per group. On the right, the molecular masses of the proteins (in kilodaltons)
are indicated. Actin levels showed that the same amounts of proteinwere loaded on the gel. Three independent experiments were carried out, and a representative
image is shown. (C) IL-6 levels in serum of ISG15/ (black bars), OTU (gray bars), or WT (white bars) mice infected with VVE3L (108 PFU/mouse) were
measured by enzyme-linked immunosorbent assay (ELISA) from serum collected at 3 hpi. Three independent experiments were carried out, and a representative
experiment is shown. Each result represents themean SD for pooled samples from6mice. Student’s t test was performed to determine theP value (,P	 0.01).
(D) ISG15/ and ISG15/micewere inoculated intraperitoneallywith poly(I:C) (10mg/kg), LPS (15mg/kg), and zymosan (15mg/kg), and the survival curves
of all the groups (n 12) were represented. Two independent experiments were carried out, and results of a representative experiment are shown. (E) IL-6 levels
in serum of ISG15/ (black bars) or WT (white bars) mice inoculated intraperitoneally with poly(I:C) (10 mg/kg), LPS (15 mg/kg), and zymosan (15 mg/kg)
were measured by ELISA from serum collected at 3 hpi. Three independent experiments were carried out, and results of a representative experiment are shown.
Results represent the means SD for pooled samples from 6 mice. Student’s t test was performed to determine the P value (, P	 0.05; , P	 0.01.
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infected with VVE3L showed an 8-fold increase in serum levels
of IL-6 compared to those for ISG15/ or OTU infected mice
(P 	 0.01) (Fig. 4C). There were no changes in levels of other
cytokines analyzed between the groups (not shown). Cytokine
and chemokine release occurs rapidly in response to virus infec-
tion, with the aim of recruiting inflammatory leukocytes in order
to limit virus replication and spread and to induce adaptive im-
munity. However, prolonged expression of chemokines in the
context of viral infectionsmay be detrimental to the host, provok-
ing the so-called cytokine storm. Here, we demonstrated that in
the absence of nonconjugated ISG15, VVE3L infection produces
an increase of IL-6 that correlates with short-term morbidity and
complications that include pulmonary function abnormalities,
indicating that free ISG15 might be involved in the downregula-
tion of IL-6 induction, facilitating a balanced, nonpathogenic in-
nate immune response. To verify that the morbidity was induced
by VVE3L infection, we evaluated the survival rate of ISG15/
and ISG15/ mice inoculated with different inflammatory
agents, such as poly(I:C) (10 mg/kg), lipopolysaccharide (LPS)
(15 mg/kg), and zymosan (15 mg/kg) (Fig. 4D). In all cases, the
survival kinetics was similar between the two types of mice and no
differences in the IL-6 levels in the serum of the treated mice were
observed (Fig. 4E). This result indicates that VVE3L infection
was the cause of themortality and also caused exacerbated levels of
IL-6 in ISG15/ mice. Whether these effects are due to the ab-
sence of E3 directly or to another process, the mechanisms of this
ISG15-dependent, ISGylation-independent regulation remain to
be determined, but it appears that ISG15 controls the antiviral
response in multiple ways, depending on whether it is or is not
conjugated. Also, it is important to underscore that free ISG15
becomes secreted and the lack of secreted ISG15 is associated with
severe mycobacterial disease in both mice and humans (37). Fur-
thermore, we recently reported the importance of ISG15 in regu-
lating macrophage activity (38), indicating that ISG15 is a crucial
molecule in the regulation of the immune response. Additional
studies to understand the biological functions of unconjugated
intracellular and/or extracellular ISG15 and of ISGylation may
help our knowledge of innate immunity and on how viruses have
developed strategies to subvert it.
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